{"id":"cyclophosphamide-cy","safety":{"commonSideEffects":[{"rate":"60-90","effect":"Myelosuppression (neutropenia, thrombocytopenia)"},{"rate":"60-90","effect":"Nausea and vomiting"},{"rate":"60-90","effect":"Alopecia"},{"rate":"5-40","effect":"Hemorrhagic cystitis"},{"rate":"variable","effect":"Infertility"},{"rate":"1-5","effect":"Secondary malignancies"},{"rate":"40-60","effect":"Immunosuppression/infection risk"}]},"_chembl":null,"_dailymed":{"setId":"1d3396d8-4c03-4a28-890a-d87c6c53a74e","title":"CYCLOPHOSPHAMIDE INJECTION, POWDER, FOR SOLUTION [BLUEPOINT LABORATORIES]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cyclophosphamide is a nitrogen mustard derivative that requires hepatic activation to form active metabolites. These metabolites covalently bind to DNA, creating inter- and intra-strand cross-links that inhibit DNA replication and transcription, leading to apoptosis in rapidly dividing cells. It also has immunosuppressive properties through lymphocyte depletion.","oneSentence":"Cyclophosphamide is an alkylating agent that cross-links DNA strands, preventing cell division and causing cancer cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:08:23.458Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Lymphomas (Hodgkin and non-Hodgkin)"},{"name":"Breast cancer"},{"name":"Ovarian cancer"},{"name":"Lung cancer"},{"name":"Severe autoimmune diseases (systemic lupus erythematosus, vasculitis)"}]},"trialDetails":[{"nctId":"NCT02287311","phase":"PHASE1","title":"Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2015-02","conditions":"Hodgkin Disease, Non-Hodgkin Lymphoma, Severe Chronic Active Epstein Barr Virus","enrollment":38},{"nctId":"NCT07101588","phase":"PHASE4","title":"Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2025-01-01","conditions":"Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)","enrollment":200},{"nctId":"NCT06743126","phase":"PHASE3","title":"SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma","status":"RECRUITING","sponsor":"Immatics US, Inc.","startDate":"2025-01-14","conditions":"Melanoma, Cutaneous Malignant","enrollment":360},{"nctId":"NCT07480928","phase":"PHASE1, PHASE2","title":"Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma","status":"RECRUITING","sponsor":"Beijing Biotech","startDate":"2026-02-02","conditions":"Pancreatic Ductal Adenocarcinoma (PDAC), Unresectable Locally Advanced or Metastatic Disease","enrollment":42},{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT04347616","phase":"PHASE1, PHASE2","title":"Natural Killer-cell Therapy for Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Radboud University Medical Center","startDate":"2020-12-03","conditions":"Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, Relapsed, Adult","enrollment":9},{"nctId":"NCT01804634","phase":"PHASE2","title":"Reduced Intensity Haploidentical BMT for High Risk Solid Tumors","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2013-03-27","conditions":"Refractory and/or Relapsed Metastatic Solid Tumors","enrollment":60},{"nctId":"NCT02648282","phase":"PHASE2","title":"Study With CY, Pembrolizumab, GVAX Pancreas Vaccine, and SBRT in Patients With Locally Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2016-07-18","conditions":"Pancreatic Cancer","enrollment":58},{"nctId":"NCT01962636","phase":"NA","title":"Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2016-12","conditions":"Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myelogenous Leukemia","enrollment":200},{"nctId":"NCT03070327","phase":"PHASE1","title":"BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-02-27","conditions":"Multiple Myeloma","enrollment":20},{"nctId":"NCT06121297","phase":"PHASE1, PHASE2","title":"RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus","status":"RECRUITING","sponsor":"Cabaletta Bio","startDate":"2024-02-16","conditions":"Systemic Lupus Erythematosus, Lupus Nephritis","enrollment":28},{"nctId":"NCT04224558","phase":"PHASE1, PHASE2","title":"Stem Cell Transplantation in Crohn's Disease","status":"RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2019-11-15","conditions":"Crohn Disease","enrollment":15},{"nctId":"NCT07410676","phase":"PHASE1, PHASE2","title":"EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Essen Biotech","startDate":"2026-02-01","conditions":"Cancer, Sarcoma, Leukaemia","enrollment":83},{"nctId":"NCT05027945","phase":"PHASE2","title":"A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-02-23","conditions":"Immunodeficiency, Hematopoietic Stem Cell Transplantation","enrollment":54},{"nctId":"NCT04067414","phase":"PHASE1","title":"Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2018-06-08","conditions":"Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Transformed Lymphoma","enrollment":12},{"nctId":"NCT03579875","phase":"PHASE2","title":"Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2018-11-13","conditions":"Fanconi Anemia, Severe Aplastic Anemia, Myelodysplastic Syndromes","enrollment":48},{"nctId":"NCT02065362","phase":"PHASE1","title":"TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2015-02","conditions":"EBV-positive Nasopharyngeal Carcinoma","enrollment":14},{"nctId":"NCT03842696","phase":"PHASE1, PHASE2","title":"Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2020-02-04","conditions":"Hematologic Diseases, Acute Leukemia in Remission, Chronic Myelogenous Leukemia - Chronic Phase","enrollment":43},{"nctId":"NCT06252870","phase":"PHASE2","title":"Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2024-07-18","conditions":"Graft Versus Host Disease, Hematologic Malignancy","enrollment":82},{"nctId":"NCT01140373","phase":"PHASE1","title":"Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2010-06","conditions":"Prostate Cancer","enrollment":13},{"nctId":"NCT06946225","phase":"PHASE1","title":"ACTengine® IMA203 Combined With mRNA-4203","status":"RECRUITING","sponsor":"Immatics US, Inc.","startDate":"2025-07-25","conditions":"Cutaneous Melanoma, Synovial Sarcoma","enrollment":15},{"nctId":"NCT07324889","phase":"PHASE1, PHASE2","title":"An Open-label, Single-arm, Prospective, Multicenter, Phase I/II Clinical Study on the Safety and Efficacy of CD19/BCMA CAR-T Cell Therapy for Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia","status":"NOT_YET_RECRUITING","sponsor":"Yihao Wang","startDate":"2026-01-31","conditions":"Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia","enrollment":24},{"nctId":"NCT03674411","phase":"PHASE2","title":"Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2019-01-02","conditions":"Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Biphenotypic/Undifferentiated Leukemia","enrollment":22},{"nctId":"NCT07319000","phase":"PHASE2","title":"Efficacy of Low-dose PT-Cy for Prevention of GVHD in Ambulatory Allogeneic HSCT","status":"COMPLETED","sponsor":"Hospital Universitario Dr. Jose E. Gonzalez","startDate":"2023-01-01","conditions":"Graft Versus Host Disease","enrollment":35},{"nctId":"NCT07297914","phase":"PHASE2, PHASE3","title":"Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL","status":"NOT_YET_RECRUITING","sponsor":"Bambino Gesù Hospital and Research Institute","startDate":"2026-01-15","conditions":"Acute Lymphoblastic Leukemia (ALL), Stem Cell Transplant, Graft -Versus-host-disease","enrollment":1000},{"nctId":"NCT01349101","phase":"PHASE2","title":"A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2011-02-10","conditions":"Hematological Malignancies","enrollment":78},{"nctId":"NCT07100873","phase":"PHASE1","title":"A Phase 1 Study of ADI-001 in Rheumatoid Arthritis","status":"RECRUITING","sponsor":"Adicet Therapeutics","startDate":"2025-10-10","conditions":"Rheumatoid Arthritis (RA)","enrollment":25},{"nctId":"NCT04864054","phase":"PHASE1, PHASE2","title":"T-Cell Therapy (ECT204) in Adults With Advanced HCC","status":"RECRUITING","sponsor":"Eureka Therapeutics Inc.","startDate":"2022-03-11","conditions":"Hepatocellular Carcinoma, Liver Cancer, Adult, Liver Neoplasm","enrollment":20},{"nctId":"NCT06520163","phase":"PHASE3","title":"Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma","status":"RECRUITING","sponsor":"The Affiliated People's Hospital of Ningbo University","startDate":"2024-08-01","conditions":"Non-Hodgkin's Lymphoma, Hematopoietic Stem Cell Mobilization","enrollment":99},{"nctId":"NCT02451982","phase":"PHASE2","title":"Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2016-03-28","conditions":"Pancreatic Cancer","enrollment":76},{"nctId":"NCT06782932","phase":"PHASE1, PHASE2","title":"Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2025-05-27","conditions":"Pancreatic Cancer","enrollment":38},{"nctId":"NCT07259070","phase":"PHASE1, PHASE2","title":"Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-11-29","conditions":"DLBCL, CLL, FL","enrollment":20},{"nctId":"NCT04232085","phase":"PHASE2","title":"Regenerative Medicine to Restore Hematopoiesis and Immune Function in Immunodeficiencies and Inherited Bone Marrow Failures","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2020-02-12","conditions":"Primary Immune Deficiency Disorder, Immune Deficiency Disease, Bone Marrow Failure","enrollment":27},{"nctId":"NCT05389514","phase":"","title":"Intermediate-size IND for Treatment of KRAS G12V-mutant Tumors","status":"TEMPORARILY_NOT_AVAILABLE","sponsor":"Providence Health & Services","startDate":"","conditions":"KRAS G12V Mutant Advanced Epithelial Cancers","enrollment":""},{"nctId":"NCT02996773","phase":"PHASE1","title":"Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine","status":"COMPLETED","sponsor":"University of Arizona","startDate":"2016-11-29","conditions":"Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndromes","enrollment":50},{"nctId":"NCT07225439","phase":"PHASE1","title":"Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)","status":"NOT_YET_RECRUITING","sponsor":"Paolo Caimi, MD","startDate":"2025-12","conditions":"Non Hodgkin Lymphoma, B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma","enrollment":15},{"nctId":"NCT03125642","phase":"PHASE2","title":"Auto Stem Cell Transplant for Lymphoma Patients","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2017-04-20","conditions":"Non-Hodgkin Lymphoma, Hodgkin Lymphoma","enrollment":150},{"nctId":"NCT02828592","phase":"PHASE2","title":"Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia","status":"RECRUITING","sponsor":"Northside Hospital, Inc.","startDate":"2016-09-09","conditions":"Severe Aplastic Anemia","enrollment":20},{"nctId":"NCT00881920","phase":"PHASE1","title":"Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2009-07","conditions":"Lymphoma, Myeloma, Leukemia","enrollment":54},{"nctId":"NCT03016806","phase":"","title":"Umbilical Cord Blood Transplantation From Unrelated Donors","status":"RECRUITING","sponsor":"University of Rochester","startDate":"2015-06","conditions":"Acute Leukemia, Immune Deficiency Disorder, Congenital Hematological Disorder","enrollment":30},{"nctId":"NCT07168486","phase":"PHASE1","title":"CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas","status":"ENROLLING_BY_INVITATION","sponsor":"University of Maryland, Baltimore","startDate":"2024-10-28","conditions":"B-Cell Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL)","enrollment":15},{"nctId":"NCT05884333","phase":"PHASE2","title":"Cord Blood Transplant in Adults With Blood Cancers","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-05-22","conditions":"Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Chronic Myelogenous Leukemia (CML)","enrollment":54},{"nctId":"NCT01088789","phase":"PHASE2","title":"Boost GVAX Pancreas Vaccine With or Without CY in Patients With Pancreas Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2010-04-20","conditions":"Pancreatic Cancer","enrollment":71},{"nctId":"NCT07085728","phase":"PHASE2","title":"Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure","status":"NOT_YET_RECRUITING","sponsor":"Eastern Cooperative Oncology Group","startDate":"2025-08-11","conditions":"Myeloma Multiple","enrollment":74},{"nctId":"NCT02793544","phase":"PHASE2","title":"HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide","status":"COMPLETED","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2016-12","conditions":"Myelodysplastic Syndrome (MDS), Chronic Lymphocytic Leukemia (CLL), Chemotherapy-sensitive Lymphoma","enrollment":80},{"nctId":"NCT03575351","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas","status":"COMPLETED","sponsor":"Celgene","startDate":"2018-10-23","conditions":"Lymphoma, Non-Hodgkin","enrollment":184},{"nctId":"NCT02917083","phase":"PHASE1","title":"CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)","status":"RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2017-05-08","conditions":"Hodgkin's Lymphoma, Non-Hodgkin Lymphoma","enrollment":60},{"nctId":"NCT06518668","phase":"PHASE1","title":"A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus","status":"RECRUITING","sponsor":"Columbia University","startDate":"2024-07-01","conditions":"Systemic Lupus Erythematosus","enrollment":6},{"nctId":"NCT06984536","phase":"PHASE2","title":"Reduced ATG Plus Mini PTCy for GVHD Prophylaxis in Haplo-SCT","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-05-21","conditions":"Myelodysplastic Syndrome, Acute Leukemia","enrollment":40},{"nctId":"NCT05735717","phase":"PHASE2","title":"MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2023-05-11","conditions":"Hematologic Malignancy, Acute Leukemia, Remission","enrollment":70},{"nctId":"NCT07059156","phase":"PHASE2, PHASE3","title":"Multicenter Study of Combined Chemotherapy and Transplantation for Adult ALL","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-06-01","conditions":"Acute Lymphoblastic Leukemia, Adult","enrollment":50},{"nctId":"NCT05805605","phase":"PHASE2","title":"Allo HSCT Using RIC and PTCy for Hematological Diseases","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2023-05-01","conditions":"Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Biphenotypic Acute Leukemia","enrollment":56},{"nctId":"NCT06680661","phase":"PHASE2","title":"ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis","status":"RECRUITING","sponsor":"Leland Metheny","startDate":"2025-02-25","conditions":"Acute Myelogenous Leukemia, Acute Lymphatic Leukemia, Chronic Myelogenous Leukemia","enrollment":20},{"nctId":"NCT06108739","phase":"PHASE3","title":"ATG Plus Low-dose PT-Cy for GVHD Prevention","status":"TERMINATED","sponsor":"Peking University People's Hospital","startDate":"2023-11-01","conditions":"Hematologic Malignancy","enrollment":66},{"nctId":"NCT02988466","phase":"PHASE2","title":"Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2017-01-24","conditions":"Hematologic Malignancies","enrollment":78},{"nctId":"NCT01532635","phase":"PHASE2","title":"A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2012-03","conditions":"Hematologic Malignancy, Leukemia, Acute Lymphoblastic Leukemia","enrollment":4},{"nctId":"NCT00429143","phase":"PHASE1, PHASE2","title":"A Two-Step Approach to Bone Marrow Transplant Using Cells From A Partially-Matched Relative","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2006-01","conditions":"Hematologic Malignancies","enrollment":27},{"nctId":"NCT04547049","phase":"PHASE3","title":"A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2020-09-01","conditions":"Leukemia","enrollment":176},{"nctId":"NCT06892223","phase":"PHASE2","title":"Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation","status":"RECRUITING","sponsor":"Istituto Clinico Humanitas","startDate":"2021-12-03","conditions":"Acute Myeloid Leukaemia, MDS (Myelodysplastic Syndrome), MPN (Myeloproliferative Neoplasms)","enrollment":42},{"nctId":"NCT06809699","phase":"PHASE1","title":"Human Leukocyte Antigen (HLA) Mismatched Related Allogeneic Hematopoietic Stem Cell Transplantation","status":"RECRUITING","sponsor":"He Huang","startDate":"2022-08-04","conditions":"Hematologic Diseases","enrollment":29},{"nctId":"NCT06809712","phase":"PHASE1","title":"Human Leukocyte Antigen (HLA) Mismatched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation","status":"RECRUITING","sponsor":"He Huang","startDate":"2022-08-04","conditions":"Hematologic Disease","enrollment":29},{"nctId":"NCT05298358","phase":"PHASE1","title":"RIC alloBMT With Post-transplant Cyclophosphamide for Refractory Systemic Sclerosis","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2022-11-18","conditions":"Systemic Sclerosis","enrollment":1},{"nctId":"NCT03161379","phase":"PHASE2","title":"GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2018-02-02","conditions":"Pancreatic Cancer","enrollment":31},{"nctId":"NCT00977691","phase":"PHASE1, PHASE2","title":"Haploidentical PBMC Transplant for Severe Congenital Anemias","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2009-12-14","conditions":"Sickle Cell Anemia","enrollment":23},{"nctId":"NCT05885464","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beam Therapeutics Inc.","startDate":"2023-05-25","conditions":"Lymphoblastic Lymphoma, T-Cell Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Leukemia","enrollment":5},{"nctId":"NCT03153410","phase":"EARLY_PHASE1","title":"Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2018-09-27","conditions":"Pancreatic Cancer","enrollment":11},{"nctId":"NCT06758726","phase":"NA","title":"Mitoxantrone Hydrochloride Liposome Combined With BU/Cy Were Used as a Conditioning Regimen for Patients With Intermediate/Adverse Risk or Persistently Positive MRD AML","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-12-31","conditions":"AML","enrollment":20},{"nctId":"NCT05714670","phase":"PHASE2","title":"The Effect of Curcumin on the Clinical Outcome of Pediatric Patients with Active Lupus Nephritis","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2023-04-01","conditions":"Lupus Nephritis, SLE Nephritis","enrollment":72},{"nctId":"NCT06673459","phase":"PHASE3","title":"BuCy Vs. TBICy for Allo-HSCT in T-ALL Patients","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2024-12-01","conditions":"T-Cell Lymphocytic Leukemia, ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Total Body Irradiation","enrollment":430},{"nctId":"NCT03006302","phase":"PHASE2","title":"Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2018-01-31","conditions":"Metastatic Pancreatic Adenocarcinoma","enrollment":41},{"nctId":"NCT03743246","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)","status":"TERMINATED","sponsor":"Celgene","startDate":"2018-10-17","conditions":"Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin","enrollment":21},{"nctId":"NCT01595321","phase":"PHASE2","title":"Pancreatic Tumor Cell Vaccine (GVAX), Cyclophosphamide, SBRT, and FOLFIRINOX in Patients With Resected Adenocarcinoma of the Pancreas","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2012-10-29","conditions":"Pancreatic Cancer","enrollment":19},{"nctId":"NCT04009525","phase":"PHASE4","title":"Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major: A Multicenter, Prospective Clinical Study","status":"COMPLETED","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2019-07-05","conditions":"Thalassemia Major","enrollment":823},{"nctId":"NCT03190265","phase":"PHASE2","title":"Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2017-12-14","conditions":"Pancreatic Cancer","enrollment":61},{"nctId":"NCT03318016","phase":"PHASE1","title":"Arsenic Trioxide With Cyclophosphamide in Patients With Relapsed/Refractory Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"University of Colorado, Denver","startDate":"2017-12-15","conditions":"Acute Myeloid Leukemia, Relapsed/Refractory Acute Myeloid Leukemia","enrollment":5},{"nctId":"NCT06520176","phase":"PHASE3","title":"Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients","status":"RECRUITING","sponsor":"The Affiliated People's Hospital of Ningbo University","startDate":"2024-08","conditions":"Multiple Myeloma, Hematopoietic Stem Cell Mobilization","enrollment":99},{"nctId":"NCT03367546","phase":"PHASE2","title":"Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (HaploHCT) Following Reduced Intensity Conditioning (RIC) for Selected High Risk Non-Malignant Diseases","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2018-07-02","conditions":"Sickle Cell Disease, Thalassemia, High Risk Hematologic Disorders","enrollment":5},{"nctId":"NCT06490562","phase":"NA","title":"Low-dose Cyclophosphamide or CNI in the Prevention of Acute Graft-versus-host Disease After gDLI","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-07","conditions":"Acute Graft-versus-host Disease","enrollment":66},{"nctId":"NCT05613348","phase":"PHASE1, PHASE2","title":"CD19 CAR T-cell Target Relapsed/Refractory Acute B Cell Leukemia/Lymphoma","status":"WITHDRAWN","sponsor":"Zhujiang Hospital","startDate":"2022-12-01","conditions":"B-cell Acute Lymphoblastic Leukemia, B-Cell Lymphoma, Unspecified","enrollment":""},{"nctId":"NCT06238245","phase":"PHASE2","title":"Combination of ATG-based Conditioning Regimen and PTCy for GVHD Prevention in Allo-HSCT After PD-1 Blockade","status":"NOT_YET_RECRUITING","sponsor":"Beijing 302 Hospital","startDate":"2024-02-28","conditions":"Graft-versus-host Disease, Hematological Malignancies","enrollment":22},{"nctId":"NCT02995330","phase":"PHASE1","title":"Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2017-02-09","conditions":"Prostate Cancer","enrollment":3},{"nctId":"NCT00630565","phase":"PHASE2, PHASE3","title":"Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2006-07-26","conditions":"Leukemia","enrollment":12},{"nctId":"NCT01949129","phase":"PHASE2, PHASE3","title":"Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia","status":"RECRUITING","sponsor":"St. Anna Kinderkrebsforschung","startDate":"2013-04","conditions":"Acute Lymphoblastic Leukaemia","enrollment":1800},{"nctId":"NCT06173726","phase":"EARLY_PHASE1","title":"Investigator-initiated Phase I Exploratory Clinical Study of the Safety, Tolerability, and Efficacy of BST02 Injection in the Treatment of Locally Advanced/Metastatic Liver Cancer","status":"NOT_YET_RECRUITING","sponsor":"BioSyngen Pte Ltd","startDate":"2023-12-05","conditions":"Locally Advanced/Metastatic Liver Cancer","enrollment":6},{"nctId":"NCT06155188","phase":"NA","title":"Post-transplant PT/FLU+CY Promotes Unrelated Cord Blood Engraftment in Haplo-cord Setting in Childhood Leukemia","status":"RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2019-09-29","conditions":"Leukemia, Stem Cell Transplant, Cord Blood","enrollment":60},{"nctId":"NCT05029206","phase":"","title":"Hematopoietic Stem Cell Transplantation for Treatment of Multiple Sclerosis in Sweden","status":"COMPLETED","sponsor":"Uppsala University","startDate":"2021-05-05","conditions":"Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting","enrollment":174},{"nctId":"NCT06133556","phase":"PHASE2","title":"Conditioning Regimen Containing Melphalan and Cladribine for Refractory / Relapsed AML","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2023-11-24","conditions":"Acute Myeloid Leukemia","enrollment":237},{"nctId":"NCT02188368","phase":"PHASE2","title":"Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients","status":"TERMINATED","sponsor":"Oncotherapeutics","startDate":"2014-07-07","conditions":"Multiple Myeloma","enrollment":45},{"nctId":"NCT03608059","phase":"PHASE4","title":"ATG/PTCy in Haplo-PBSCT Randomized Controlled,Multi-center","status":"COMPLETED","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2018-07-28","conditions":"Myeloid Tumor","enrollment":418},{"nctId":"NCT05768035","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of SMART101 in Adult Patients With Hematological Malignancies After Haploidentical HSCT With Post-transplant Cyclophosphamide","status":"RECRUITING","sponsor":"Smart Immune SAS","startDate":"2023-06-06","conditions":"Hematological Malignancies","enrollment":40},{"nctId":"NCT05395052","phase":"PHASE1","title":"FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors","status":"TERMINATED","sponsor":"Fate Therapeutics","startDate":"2022-05-31","conditions":"Non Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer","enrollment":5},{"nctId":"NCT05293509","phase":"PHASE2","title":"Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-03-02","conditions":"Stem Cell Transplantation","enrollment":""},{"nctId":"NCT05069935","phase":"PHASE1","title":"FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors","status":"TERMINATED","sponsor":"Fate Therapeutics","startDate":"2021-10-15","conditions":"Solid Tumor, Adult","enrollment":16},{"nctId":"NCT05063513","phase":"PHASE2, PHASE3","title":"Autologous Stem Cell Transplantation: International Lupus Trial","status":"WITHDRAWN","sponsor":"European Society for Blood and Marrow Transplantation","startDate":"2009-07","conditions":"REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS","enrollment":""},{"nctId":"NCT01639573","phase":"","title":"Campath-1h Phase I/II Pilot Trial as Immunoablative Therapy for Refractory Systemic Sclerosis","status":"WITHDRAWN","sponsor":"Children's Hospital Los Angeles","startDate":"2011-04","conditions":"Scleroderma","enrollment":""},{"nctId":"NCT05629260","phase":"","title":"The Optimization of Haploidentical Hematopoietic Stem Cell Transplantation","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2022-12-01","conditions":"Hematological Malignancy","enrollment":300},{"nctId":"NCT03050216","phase":"PHASE2","title":"QUILT-3.033: Haplo NK With SQ ALT-803 for Adults With Relapsed or Refractory AML","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2017-05-16","conditions":"Acute Myeloid Leukemia","enrollment":8},{"nctId":"NCT05929092","phase":"NA","title":"TFBC Combined With UCBT in the Treatment of High-risk Malignant Hematological Diseases","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2023-06-01","conditions":"Hematopoietic Stem Cell Transplantation, Malignant Hematological Diseases","enrollment":40},{"nctId":"NCT00003910","phase":"PHASE2","title":"Methotrexate With or Without Cyclophosphamide in Treating Patients With Lymphocytic Leukemia","status":"TERMINATED","sponsor":"Eastern Cooperative Oncology Group","startDate":"1999-09-15","conditions":"Leukemia","enrollment":59},{"nctId":"NCT00093834","phase":"PHASE1","title":"Vaccine Therapy With or Without Cyclophosphamide and Doxorubicin in Women With Stage IV Breast Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2004-01","conditions":"Breast Cancer","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2434,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CY","Endoxan","Cytoxan","Neosar","Procytox"],"phase":"marketed","status":"active","brandName":"Cyclophosphamide (CY)","genericName":"Cyclophosphamide (CY)","companyName":"Nanfang Hospital, Southern Medical University","companyId":"nanfang-hospital-southern-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cyclophosphamide is an alkylating agent that cross-links DNA strands, preventing cell division and causing cancer cell death. Used for Lymphomas (Hodgkin and non-Hodgkin), Breast cancer, Ovarian cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}